Personalized Treatment for Hypertension in Heart Failure
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epidemiology".
Deadline for manuscript submissions: 10 December 2024 | Viewed by 59
Special Issue Editor
Special Issue Information
Dear Colleagues,
Heart failure (HF) is classified into three types based on left ventricular contractility (ejection fraction (EF)). HF-reduced EF has been established to be treated with many cardioprotective medications, including the fantastic four. On the other hand, cardioprotective medications that have evidence of HF mildly reduced EF (HFmrEF) and HF-preserved EF (HFpEF) are sodium/glucose cotransporter 2 inhibitors only, and their treatment is often difficult. However, in an aging society, HFmrEF and HFpEF are on the rise. Therefore, especially in these types of HF, it is also important to suppress their progression to the symptomatic HF stage (stage C HF). Hypertension (HT) is a major cause of decreased cardiac diastolic function in HFpEF, and blood pressure control is possible to suppress symptomatic HF; however, the mechanism behind this is poorly understood.
The aim of this Special Issue is to bring new inspiration to daily clinical practice by discussing the mechanisms that induce HF in patients with HT.
In this Special Issue, we are broadly soliciting reports on epidemiological studies and original research on HT and HF. Reviews are also welcome. We look forward to receiving your contributions.
Dr. Shunsuke Kiuchi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypertension
- heart failure
- prevention
- left ventricular contractility
- cardiovascular outcomes
- cardiology
